• SENSEX 82,104.79
    512.34 (+0.63%)
  • BANKNIFTY 61,575.90
    541.80 (+0.89%)
Back

Results - Announcements

Medicamen Biotech Ltd share price gained 4.59% to Rs 282.7

Medicamen Biotech Ltd consolidated sales up 14.47% on year in Q2FY2027, net profit saw a strong growth of 122.70%
15-Nov-2026, 12:00

Medicamen Biotech Ltd's net profit soared by 122.70% to Rs 4.12 crore, while revenue from operations increased 14.47% to Rs 54.83 crore in Q2FY27 over Q2FY26.


The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 27.83 lakh crore, rising 6.94%. It has improved by 2.52% over last one week and ticked higher by 5.98% in last one month while the market capitalization of Medicamen Biotech Ltd has marginally improved by 2.65% and 21.76% in the same period respectively.


Profit before tax (PBT) of Medicamen Biotech Ltd stood at Rs 5.12 crore in Q2 FY27, surging by 91.04% year-on-year, and jumping 99.22% quarter-on-quarter. EBITDA came in at Rs 9 crore, expanding by 81.21% YoY and rallying 150.14% sequentially.


Total expenses posted a minor rise of 5.86% to Rs 48.02 crore in Q2FY27 over Q2FY26. During the quarter, cost of materials consumed stood at Rs 11.07 crore, plunging by 51.04% YoY, while employee benefits expense was at Rs 9.65 crore, inching up 3.65% YoY.


For FY26, revenue from operations jumped by 21.67% to Rs 197.77 crore, while net profit jumped 49.39% to Rs 9.8 crore, compared to previous FY. EBITDA witnessed a strong improvement of 677% to Rs 16.48 crore, and PBT witnessed a strong rise of 21.26% to Rs 11.98 crore compared to previous FY.


The company's consolidated net cash flow from operating activities stood at Rs 33.17 crore in FY26, as against Rs 7.19 crore in FY25.


Medicamen Biotech Ltd nosedived by 31.56% in last one year, underperforming the benchmark BSE Sensex which has softened by 3.42% during the same period.